Work

The Diflunisal Trial: Study accrual and drug tolerance

Year: 2012

Type: article

Source: Amyloid

DOI: 10.3109/13506129.2012.678509

Authors: John L. Berk, Ole B. Suhr, Yoshiki Sekijima, Taro Yamashita, Michael Heneghan, Steven R. Zeldenrust, Yukio Ando, Shu-ichi Ikeda, Peter Gorevic, Giampaolo Merlini, Jeffrey W. Kelly, Martha Skinner, Alice B. Bisbee, Peter J. Dyck, Laura Obici, the Familial Amyloidosis Consortium

Institutions: Boston University, Boston Medical Center, Umeå University, Shinshu University, Kumamoto University, King's College Hospital, Mayo Clinic, Mount Sinai Health System, University of Pavia, Scripps Research Institute

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, U.S. Food and Drug Administration, Japan Society for the Promotion of Science, National Institute of Neurological Disorders and Stroke, National Center for Research Resources

Awards: Analysis of autoantibodies for targeting pathogenesis and therapyof misfolding diseases, Effect of diflunisal (IND68092) on familial amyloidosis, G5058676250, Boston University Clinical and Translational Science Award (CTSA) Program UL1, Early diagnosis and analyses of the pathogenesis for amyloidosis with all our previous investigations, G7326798165, G761499709, Establishment of early diagnosis method and new non-invasive therapy for transthyretin amyloidosis

OpenAlex ID: W2125488554

FWCI: 3.135

Cites: 7

Cited by: 39

Related to: 10